Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study
Citations Over TimeTop 14% of 2016 papers
Abstract
Lung cancer ranks as the most common and lethal malignancy in America and worldwide. APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors. In this study, we combine the data of online databases and two hundred and twenty-one primary non-small-cell lung carcinoma (NSCLC) specimens from Sun Yat-sen University Cancer Center to investigate, for the first time, the clinical role of APOBEC3B in lung cancer. We found that the APOBEC3 expression was commonly elevated in NSCLC tissues and overexpression of APOBEC3B was correlated with unfavorable prognosis of the patients with NSCLC. Furthermore, APOBEC3B expression was associated with nodal status, TNM staging and adjuvant chemotherapy of the patients with NSCLC. Further research is warranted.
Related Papers
- Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase.(1997)
- → Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells(1998)18 cited
- Cytotoxic effects of 5 fluorocytosine on hepatocarcinoma cells transduced with cytosine deaminase gene in vitro(1999)
- The study of cytosine deaminase gene/5 - fluorocytosine in tumor gene therapy(2000)
- Combined cytosine deaminase and uracil phosphoribosyl transferase gene therapy for gastric cancer xenografts in nude mice(2003)